Spencer Simon, PA
Physician Assistant · Eden, NCNPI 1679536296
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 52.2% of the total. 2025 is the largest year on record at $88,788, more than ten times the $2,021 reported in 2021. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $145.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$50K
- Johnson & Johnson$18K
- Teva Pharmaceuticals USA, Inc.$17K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Lundbeck LLC$1K
- AbbVie$991
- plus $6K from 19 others
What the payments were for
- Consulting fees$14,10315%
- Speaking & faculty fees$47,98850%
- Travel & lodging$19,99221%
- Food & beverage$13,02714%
- Education$2870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 83 | $49,817 |
| Johnson & Johnson | 64 | $17,974 |
| Teva Pharmaceuticals USA, Inc. | 87 | $16,725 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $3,264 |
| Lundbeck LLC | 23 | $1,037 |
| AbbVie | 71 | $991 |
| Alkermes, Inc. | 47 | $969 |
| Otsuka America Pharmaceutical, Inc. | 44 | $743 |
| Neurocrine Biosciences, Inc. | 19 | $652 |
| USWM, LLC | 30 | $581 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $465 |
| Vanda Pharmaceuticals Inc. | 24 | $441 |
| Supernus Pharmaceuticals, Inc. | 14 | $343 |
| Sunovion Pharmaceuticals Inc. | 21 | $320 |
| Indivior Inc. | 17 | $275 |
| Almatica Pharma LLC | 7 | $149 |
| Tris Pharma Inc | 7 | $146 |
| Axsome Therapeutics, Inc. | 6 | $126 |
| Merck | 7 | $118 |
| Neos Therapeutics, LP | 5 | $92 |
| Eisai Inc. | 3 | $49 |
| Corium, LLC | 2 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$95,397 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 73 | $613,881 |
| CaplytaLumateperone Tosylate | 106 | $174,574 |
| RexultiBrexpiprazole | 44 | $74,418 |
| Invega SustennaPaliperidone Palmitate | 26 | $71,506 |
| Abilify MaintenaAripiprazole | 14 | $38,849 |
| SpravatoEsketamine Hcl | 14 | $29,487 |
| VraylarCariprazine Hcl | 15 | $23,872 |
| UzedyRisperidone | 13 | $20,832 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $13,313 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 111 | $8,544 |
| BelsomraSuvorexant | 16 | $7,797 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,478 |
| Lisdexamfetamine Dimesylate | 27 | $5,657 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 102 | $4,960 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 74 | $4,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $652 | $613,88173 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,264 | $174,574106 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $743 | $113,26758 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $17,974 | $100,99340 claims |
| AbbVieVraylar | $991 | $23,87215 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $16,725 | $20,83213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $465 | $19,79147 claims |
| MerckBelsomra | $118 | $7,79716 claims |
| Indivior Inc.Suboxone | $275 | $3,00318 claims |
| Almatica Pharma LLCSertraline Hcl | $149 | $1,547128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Eden
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.